Here's a French Biotech Investors May Not Care About Enough
- Pipeline promising, Nicox left toughest period behind: CEO
- Company obtained ‘unusual’ two approvals in U.S. this year
This article is for subscribers only.
Nicox SA, which obtained U.S. regulatory approval for two products this year, is “no longer at risk of disintegrating,” according to Chief Executive Officer Michele Garufi.
The French biotechnology company, whose stock has fallen in every year but two since 2010, when the Food and Drug Administration rejected its first product, now has a “promising pipeline” and no need for cash, Garufi said in a phone interview. Nicox has reoriented its strategy to focus on ophthalmology, and its newly approved medicines, Zerviate and Vyzulta, will start generating sales next year, he said.